SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double blind, parallel group study of 3 months'
treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An
open label safety extension to this study is planned as a separate protocol for patients who
are willing and eligible to participate.